ArticleBMC neurology2026
Long-term outcome and predictors in cerebral venous sinus thrombosis: a prospective cohort study.
Article in BMC neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Isolated Psychiatric Presentation of Cerebral Venous Thrombosis in a Patient Without Risk Factors: A Diagnostic Challenge.The American journal of case reports · 2026Article
- Cerebral Venous Sinus Thrombosis Revealing ALK-Positive Anaplastic Large-Cell Lymphoma in a Patient with Inherited Thrombophilia and Concomitant Infection: Case Report and Narrative Review.Life (Basel, Switzerland) · 2026Article
- Cerebral Veins and Dural Sinuses Thrombosis: Data from a Monocentric Cohort Study of 55 Romanian Patients.Life (Basel, Switzerland) · 2026Article
- When headache meets visual disturbance: An evidence-based review of common and critical entities.Science progressReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundAlthough cerebral venous sinus thrombosis (CVT) is a rare disease with an overall favorable prognosis, 3%-15% CVT patients may experience death or severe disability during acute phase from symptom onset. We examined clinical characteristics in CVT patients and identify predictors associated with 12-month functional outcomes in patients with newly diagnosed CVT.
methodsIn this prospective cohort study, 61 patients with newly diagnosed CVT between Jan 2024 and Aug 2025 were enrolled and followed up for 12 months. The primary outcome was functional disability at 12 months, defined by a modified Rankin Scale (mRS) score ≥ 2. Clinical, radiological, and demographic variables were assessed as potential predictors. Logistic regression was used to identify independent predictors of poor 12-month outcome.
resultsAt 12 months, fifty-seven patients (93.4%) had a favorable outcome (mRS < 2), while 4 patients (6.6%) had a poor outcome (mRS 2–4). Poor outcome was associated with higher admission NIH Stroke Scale (NIHSS) scores, impaired consciousness, brain parenchymal infarction, and extensive thrombosis. In multivariable analysis, admission NIHSS score was independently associated with poor outcome (odds ratio 1.21 per point; 95% CI 1.052–1.396). An NIHSS score ≥ 9 had a sensitivity of 75.0% and specificity of 93.0% for predicting disability at 12 months.
conclusionAn NIHSS score ≥ 9 at admission independently predicts poor 12-month outcome in CVT and may guide early risk stratification and management decisions.
trial registrationThis is a secondary analysis of prospectively collected data from the registered clinical trial (URL: https://www.chictr.org.cn ; No. ChiCTR2400080136; Registration date: Jan 22, 2024).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.